Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Tigran Makunts, Ruben Abagyan
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2024-06-01
Seri Bilgileri:	Frontiers in Psychiatry
Konular:	DILI (drug-induced liver injury) MDMA DDI (drug-drug interaction) FAERS adverse events MDMA (3,4-methylenedioxymethamphetamine)
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1414622/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!